Seeking Solutions for Brain Tumors
“We’re not in the top ranking among [hospitals conducting] clinical trials, but when you look at enrollment we are at the top of the list,” he says. “We are offering a high volume of cases, and the more you do, the
better you are; like in many disciplines, it relates to better outcomes and
Researching a prospective “tumor vaccine is something we are pursuing,” he says. In developing programs, whether telestroke or brain tumor research, “having clinical focus is absolutely critical,” Pomeroy says.
Funding sources for the Barrow programs include the National Institutes of Health, focusing on areas ranging from basic science research, advanced diagnostics, or therapeutic innovations. “I think increasing our clinical volume will be a substantial indicator of our success,” Pomeroy says.
This article appears in the September 2011 issue of HealthLeaders magazine.
Joe Cantlupe is a senior editor with HealthLeaders Media Online.
- Ebola: Health Officials Try to Quell Front Line Fears
- Reducing Readmissions Starts with Better Collaboration
- Ebola: A New Normal in Dallas
- Partners HealthCare M&A Deal Under Scrutiny
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Educated Nurses Save Money
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening
- As virus spreads, insurers exclude Ebola from new policies
- Defensive Medicine Still Prevalent Despite Tort Reform
- How Top-Ranked MA Plans Earn Their Stars